About The Study
Before emerging therapies can be approved for widespread public use, they must first be tested in controlled clinical research settings such as this one. By joining the Arise Parkinson’s disease study, participants are playing a vital role in helping doctors and scientists make meaningful progress in the field of Parkinson’s disease research, and work towards a more hopeful future for fellow PD patients.
What Are The Benefits?
By participating in this study, participants will have access to specialists who understand their unique situation and can help answer questions and address concerns. Throughout the trial, patients will be monitored in a safe, compassionate environment and participate in cutting-edge clinical innovation.
What Is Being Tested?
The main purpose of this study is to evaluate the efficacy of CVN424 (Solengepras) in patients with Parkinson’s disease, as well as how it safely interacts with the body. The intended purpose of CVN424 (Solengepras) is to target cell receptors and “put the brakes on” overactivity in the brain’s so called “indirect pathway,” which may potentially benefit participants’ motor and non-motor functions. Read our FAQs to learn more about this study, and what to expect as a participant.
From the Community…
Clinical Trials Make A Difference
When you participate in a clinical study, you provide valuable information that could eventually lead to a better treatment and—with the right breakthrough—to better outcomes. Take our brief survey to see if you are a good fit. There is no obligation.
Participate In Innovation
Shape The Future
Help Others
Still have questions?
Contact us anytime at help@clinicalenrollment.com